Description

7H-Isoquino(2,1-D)(1,4)Benzodiazepin-8-Ium, 9,10-Dihydro-6-(4-Biphenylyl)-2-Chloro-12,13-Dimethoxy-, Bromide is a complex heterocyclic organic salt of significant interest in advanced pharmaceutical research and development. This compound is valued for its unique molecular architecture, which serves as a critical intermediate or active pharmaceutical ingredient (API) in the synthesis of novel therapeutic agents. It is primarily sought by research institutions, pharmaceutical manufacturers, and fine chemical suppliers engaged in the development of central nervous system (CNS) drugs and other specialized medicinal chemistry applications.

Application

• Pharmaceutical Intermediate: A key building block in the synthesis of novel benzodiazepine-derived active pharmaceutical ingredients (APIs).
• Neurological Research: Used in preclinical studies and drug discovery programs targeting GABA receptor modulation for CNS disorders.
• Medicinal Chemistry: Serves as a sophisticated scaffold for structure-activity relationship (SAR) studies and lead optimization.
• Reference Standard: Employed as a high-purity analytical standard for quality control and method development in pharmaceutical analysis.
• Process Development: Utilized in scaling up synthetic routes for potential new chemical entities (NCEs).
• Contract Manufacturing: Supplied to CDMOs (Contract Development and Manufacturing Organizations) for custom synthesis projects.

Basic Information

Product Name	7H-Isoquino(2,1-D)(1,4)Benzodiazepin-8-Ium, 9,10-Dihydro-6-(4-Biphenylyl)-2-Chloro-12,13-Dimethoxy-, Bromide
CAS No.	62206-22-8
Molecular Formula	C31H26BrClN2O2
Molecular Weight	573.91 g/mol
Synonyms	9,10-Dihydro-6-(4-biphenylyl)-2-chloro-12,13-dimethoxy-7H-isoquino[2,1-d][1,4]benzodiazepin-8-ium bromide; 6-(1,1'-Biphenyl-4-yl)-2-chloro-9,10-dihydro-12,13-dimethoxy-7H-isoquino[2,1-d][1,4]benzodiazepin-8-ium bromide; BIBP 3226 Bromide; (R)-N2-(Diphenylacetyl)-N-[(4-hydroxyphenyl)methyl]argininamide Bromide (related research compound); BIBP3226; Y1 receptor antagonist (research context); Neuropeptide Y antagonist analog
EINECS	Contact for details

Quality Control

Our production of this high-value compound adheres to strict quality management systems, ensuring batch-to-batch consistency and traceability. Quality is verified through comprehensive analytical techniques including HPLC, NMR, and mass spectrometry. A Certificate of Analysis (COA) detailing purity, identity, and impurity profiles is provided with each shipment. We support compliance with cGMP guidelines for pharmaceutical intermediates, and specifications can be aligned with client-specific pharmacopeial requirements.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). Due to its hygroscopic nature, the container must be kept tightly sealed in a dry environment to prevent moisture absorption. For long-term storage, consider desiccants or an inert atmosphere.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥ 98.0%
Water Content (KF)	≤ 1.0%
Residue on Ignition	≤ 0.1%
Heavy Metals	≤ 20 ppm
Related Substances (HPLC)	Total impurities ≤ 2.0%; Any single impurity ≤ 0.5%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.